Filing Flows › Adia Med (ADIA) › Q2 2026 › vs Q2 2025
Adia Med (ADIA) Q2 2026 vs Q2 2025 (year over year)
Adia Med's revenue rose $367K (+311%) from $118K in Q2 2025 to $485K in Q2 2026. The biggest changes: Medical Procedures +$304K (13×); Sales of Biologics +$64K (+73%); Shipping and Delivery +$3K (+196%). Gross margin 58.2% against 21.9% (+36.3 pts).
Adia Med, Q2 2026: revenue $485K (+311% year over year), operating margin 10.7%, net earnings $40K, operating cash flow −$109K. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Gross margin | 58.2% | 21.9% | +36.3 pts |
| Operating margin | 10.7% | -98.7% | +109.4 pts |
| Net margin | 8.3% | -105.0% | +113.3 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Medical Procedures | $330K | $26K | $304K | 13× |
| Sales of Biologics | $152K | $88K | $64K | +73% |
| Shipping and Delivery | $4K | $1K | $3K | +196% |
| Revenue | $485K | $118K | $367K | +311% |
| Gross profit | $283K | $26K | $257K | +990% |
| Cost of revenue | $203K | $92K | $111K | +120% |
| Operating profit | $52K | −$117K | $168K | — |
| Operating expenses | $231K | $143K | $88K | +62% |
| Pre-tax earnings | $40K | −$124K | $164K | — |
| Other expense, net | $11K | $7K | $4K | +54% |
| Net earnings | $40K | −$124K | $164K | — |
| Operating cash sources | $151K | $14K | $137K | 11× |
| Depreciation | $1K | $1K | $302 | +26% |
| Cash used in operations | $109K | $136K | −$27K | -20% |
| Working capital & other | $151K | $14K | $137K | 11× |
Questions
How much did Adia Med's revenue grow year over year in Q2 2026?
Adia Med's revenue rose $367K (+311%) from $118K in Q2 2025 to $485K in Q2 2026.
What drove Adia Med's revenue change in Q2 2026?
Medical Procedures +$304K (13×); Sales of Biologics +$64K (+73%); Shipping and Delivery +$3K (+196%).